Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study

Blood

Volumn 92, Issue 6, 1998, Pages 1927-1932

  Coiffier, B ^a   Haioun, C ^b   Ketterer, N ^b   Engert, A ^b   Tilly, H ^b   Ma, D ^b   Johnson, P ^b   Lister, A ^b   Feuring Buske, M ^b   Radford, J A ^b   Capdeville, R ^b   Diehl, V ^b   Reyes, F ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0032530342     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase T clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-c2b8) in patients with recurrent B-cell lymphoma. Blood 84:2457, 1994
2. Reff ME, Garner K, Chambers KS, Chinn PC, Leonard JE, Rabb R, Newrnan RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435, 1994
3. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 88:637a, 1996 (abstr. suppl 1)
4. Maloney D, Grillo-López A, Bodkin D, White C, Liles T, Royston I, Yarns C, Rosenberg J, Levy R: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J Clin Oncol 15:3266, 1997
5. Maloney D, Grillo-López A, White C, Bodkin D, Schilder R, Neidhart J, Janakiraman N, Foon K, Liles T-M, Dallaire B, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188, 1997
6. McLaughlin P, Cabanillas F, Grillo-Lopez AJ, Link BK, Levy R, Czuczman M, Heyman MR, Williams M, Jain V, Bence-Bruckler I, Ho AD, Lister J, Rosenberg J, Dallaire BK, Shen D: IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 88:90a, 1996 (abstr, suppl 1)
7. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 49:2112, 1982
8. Harris NL, Jaffe ES, Stein H, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
9. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrick M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B: Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara-C and dexamethasone (DHAP). Blood 71:117, 1988
10. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, Mclaughlin P, Swan F, Romaguera JE: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734, 1995
11. Hopfinger G, Heinz R, Koller E, Schneider B, Pittermann E: Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's Iymphoma. Eur J Haematol 55:223, 1995